FDA Import Alert 66-40: What Happens When Your Drug Supplier Gets Listed
At least four foreign drug manufacturers were placed on FDA Import Alert 66-40 in Q1 2026. Here is what automatic detention without physical examination means for your supply chain and what to do before your next shipment lands.
At least four foreign drug manufacturers were placed on FDA Import Alert 66-40 in the first three months of 2026. Three are based in India or China. One is in Australia.
None of their US customers had advance notice.
If your OTC drug, API, or supplement ingredient comes from an overseas contract manufacturer, Import Alert 66-40 is the mechanism that turns a supplier's CGMP problem into your supply chain problem — immediately and without a hearing.
This is how it works, what triggers it, and what brands need to do when a supplier lands on the list.
What Import Alert 66-40 Is
Import Alert 66-40 authorizes FDA field personnel to detain shipments of human and animal drugs from foreign manufacturers — without physically inspecting the shipment — when an FDA inspection has found the facility is not operating in conformity with Current Good Manufacturing Practice (CGMP) requirements.
The formal name: Detention Without Physical Examination (DWPE).
In practice, it means that any shipment from a listed firm will be stopped at the US border and refused admission. Customs brokers and port staff do not need a new inspection or new evidence. The listing itself is sufficient grounds for refusal.
The firm goes on a "Red List." Until the listing is resolved, no product from that manufacturer enters the US market.
What Gets a Manufacturer Listed
The trigger is an FDA inspection that reveals significant CGMP violations. Placement on IA 66-40 does not always wait for a warning letter — in several 2026 cases, the firm was added to the Red List weeks before the warning letter was publicly issued.
Flowchem Pharma Private Limited (India) was placed on Import Alert 66-40 on January 22, 2026. The corresponding warning letter wasn't published until March 17. By that point, any US company sourcing APIs from Flowchem had already been dealing with detained shipments for nearly two months.
The violations FDA cited at Flowchem: inadequate equipment cleaning that created cross-contamination risk, raw materials stored outdoors, failure to establish impurity profiles, and identity testing that consisted of accepting supplier certificates of analysis without independent verification.
That last violation — relying on supplier CoAs without testing — appeared across multiple Q1 2026 IA 66-40 cases. It is one of the most common CGMP failures FDA finds at foreign drug manufacturers, and it is almost never caught by US purchasers before an inspection.
Other Q1 2026 firms placed on or confirmed to remain on IA 66-40:
- Cosmetic Manufacturers Pty Ltd. (Australia) — placed on IA 66-40 after February 2026 inspection; violations included failure to test finished products for identity and strength, insufficient process validation, use of unqualified equipment. The firm ceased US production.
- Yangzhou H&R Plastic Daily Chemical Co., Ltd. (China) — March 2026 warning letter; failure to test OTC batches for active ingredient identity and strength prior to release, no process validation, inadequate quality unit.
- Patcos Cosmetics Pvt. Ltd. (India) — March 2026 warning letter confirmed the firm remains on IA 66-40; findings included bird harborage areas, water damage in production spaces, deliberate alteration of lab data to conceal out-of-specification results.
What It Means for Your Shipments
Once a supplier is on IA 66-40, every shipment from that facility is subject to automatic DWPE at the US border. You do not get a grace period for shipments already in transit. If a container is on the water when the listing goes into effect, it will be detained when it arrives.
The practical sequence:
- Shipment arrives at port of entry
- CBP or FDA field personnel check the importer against the Red List
- Shipment is detained — no physical sampling needed
- Importer receives a Notice of FDA Action
- Importer has the option to submit evidence that the specific lot is not adulterated (private laboratory testing at importer's cost)
- Absent sufficient evidence, the shipment is refused and must be re-exported or destroyed
The cost burden falls on the US importer. Testing is required for each lot, and the standard for release is that the importer must demonstrate the specific shipment meets US safety and labeling requirements despite coming from a facility FDA has already found to be non-compliant.
In the majority of cases, importers switch suppliers rather than attempt lot-by-lot release.
How Long Does It Take to Get Off the List
There is no automatic timeline. Removal from IA 66-40 requires the manufacturer — not the US importer — to petition FDA with documented evidence that the CGMP violations have been corrected.
The firm must submit a corrective action letter plus supporting documentation to the CDER Office of Manufacturing Quality. FDA will typically require a follow-up inspection before removing the firm from DWPE.
For foreign manufacturers with open warning letters, the reinspection queue is rarely quick. Several firms currently on IA 66-40 have been listed for three or more years.
US brands sourcing from foreign contract manufacturers have no leverage in this process. The petition is between the manufacturer and FDA.
The Sourcing Risk Most Brands Don't Track
Most brands know who their contract manufacturer is. Few systematically track whether that manufacturer has received FDA 483 observations, is under a warning letter, or has been placed on an import alert.
The gap matters because the CGMP violations that precede IA 66-40 placement are often visible months before listing occurs. A 483 observation is issued at the close of an inspection. Warning letters are published on FDA's website within weeks of issuance. Import alert listings are updated on the FDA access data portal.
Each of these is a signal. The signal-to-action time is the variable that determines whether a brand is caught flat-footed or has already qualified a backup supplier.
We built Policy Canary to close that gap. When a regulatory action — 483, warning letter, import alert, recall — is published that involves a company or ingredient you have flagged, you receive an alert. Not a weekly digest. Not a manual search you run when something feels off. A direct notification when the FDA record hits.
For brands sourcing APIs, excipients, or finished dose forms from overseas manufacturers, IA 66-40 monitoring is one of the more consequential use cases. The firms on the list right now went from "active supplier" to "no product can enter the US" at the moment the listing was published.
What to Do Right Now
If your supply chain includes any foreign drug manufacturer — contract manufacturers, API suppliers, excipient suppliers, co-packers — three steps:
1. Search the IA 66-40 Red List for your suppliers. The current Red List is at accessdata.fda.gov. It is updated continuously. Search by company name and country.
2. Pull their warning letter history. A company can be headed for IA 66-40 placement well before the listing appears. If a supplier has received a warning letter in the past 18 months citing CGMP violations, they are at elevated risk of DWPE. FDA 483 observations are another leading indicator — these are available through FDA's inspection database.
3. Set up monitoring. Manual searches are a point-in-time snapshot. The Red List changes without announcement. A supplier's status can move from compliant to DWPE between the time you check and the time your next shipment departs.
Policy Canary monitors FDA regulatory actions against the specific companies and ingredients you flag, and sends alerts when something changes. If you would like to see how it works for your supply chain, start a free trial at policycanary.io.
A Pattern Worth Watching
At least 13 warning letters published in Q1 2026 mention import alert placement or result in DWPE. The majority involve foreign manufacturers of drugs, OTC products, or APIs. India and China are the most frequently cited countries of origin, consistent with the broader distribution of US drug manufacturing.
The enforcement pace is not slowing. DOGE-related staffing reductions at FDA have affected administrative and support roles, but the inspection backlog from 2024 and 2025 continues to generate CGMP enforcement actions — 135 warning letters were published in Q1 2026 alone.
Brands that depend on a single foreign manufacturer for any regulated ingredient are carrying supply chain risk that most of them are not actively measuring.
Import Alert 66-40 is how that risk becomes a logistics crisis.
Policy Canary monitors FDA warning letters, import alerts, recalls, and regulatory notices for the specific products and ingredients you care about. Monitor 5 products free at policycanary.io.
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.
